Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro.
Muramyl dipeptide (MDP), eight new lipophilic MDP derivatives (MDPs) and three purified saponins were evaluated for their ability to induce immune responses in mice immunized with HIV-1 envelope protein rgp160 and for their ability to influence the HIV-1 replication in vitro. Three of nine new synthetic MDP derivatives (beta-butyl-MDP, MTPO-26 and beta-cholesteryl-MDP) and one saponin (Taurosid I) have been shown to induce strong humoral immune responses to HIV-1 envelope glycoproteins rgp160 and rgp120. Three substances (beta-butyl-MDP, MDP-cholyl and beta-G27-MDP) induced high levels of T-cell stimulation to HIV-1 rgp160. beta-butyl-MDP induced the strongest B- and T-cell responses to HIV-1 glycoproteins. Two substances (beta-butyl-MDP and Taurosid I) did not induce an enhancement of HIV-1 replication in vitro and can be considered as promising adjuvants.
Krivorutchenko
Y L
YL
Department of Microbiology and Virology, Crimean Medical Institute, Ukraine.
Andronovskaja
I B
IB
Hinkula
J
J
Krivoshein
Y S
YS
Ljungdahl-Ståhle
E
E
Pertel
S S
SS
Grishkovets
V I
VI
Zemlyakov
A E
AE
Wahren
B
B
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D005260:Female; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012503:Saponins / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
D000276:Adjuvants, Immunologic; D012503:Saponins; D000119:Acetylmuramyl-Alanyl-Isoglutamine